PMA P100034/S013 – Optune: supplement approval extending the indication to newly diagnosed glioblastoma (2015)

Government Record · U.S. Food and Drug Administration, Center for Devices and Radiological Health · October 5, 2015

U.S. Food et al., 2015-10-05: Supplement approval of 5 October 2015 adding newly diagnosed glioblastoma to the Optune indication, in combination with temozolomide after surgery and chemoradiation.

Optune™ with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

Approval letter p.1 (5 October 2015)

U.S. Food et al., 2015-10-05: Supplement approval of 5 October 2015 adding newly diagnosed glioblastoma to the Optune indication, in combination with temozolomide after surgery and chemoradiation. The 2015 expansion the claim names; the letter restates the 2011 recurrent-GBM indication as the prior approval. Filed 10 April 2015; product code NZK; panel-track supplement. PDF text layer is clean, so the excerpt is quoted from the letter itself. Also filed as CCH-20 (claims C5). Study type: regulatory record.